The OmniAge compendium of aging omic biomarkers links mitotic clocks to clonal hematopoiesis and causality.
Key claim: OmniAge, a package of 413 aging omic biomarkers across 12 categories, links mitotic clocks to clonal hematopoiesis subtypes and causal clocks predictive of cancer risk, while showing that transcriptomic–epigenetic age-acceleration correlations in sorted immune cells are driven by cell-type heterogeneity.
Abstract
Interest in aging ‘omic’ biomarkers has grown due to their ability to quantify biological age. Most of these biomarkers have been derived in blood and fall into many diverse categories, yet relatively little is known about their correlative patterns, especially between biomarkers from different categories. Here we present the OmniAge R and Python package, a collection of 413 aging omic biomarkers representing 12 different categories, including traditional epigenetic clocks, epigenetic mitotic clocks, DNA methylation-based proxies for clonal hematopoiesis and inflammaging, causal clocks, cell-type specific epigenetic clocks and single-cell transcriptomic clocks. By studying their inter-class correlations across large blood datasets, we reveal associations of mitotic age with clonal hematopoiesis subtypes and causal clocks, which are predictive of cancer risk. Using proxies of serum protein levels, we further dissect associations with mitotic clocks, clonal hematopoiesis and causal clocks into distinct biological processes mapping to key aging pathways. Applying OmniAge to multi-modal data of sorted immune cell-types reveals that age-acceleration derived from transcriptomic and epigenetic clocks correlate, but that this is driven by underlying cell-type heterogeneity. In summary, the OmniAge package is an exploratory tool for evaluating large numbers of aging omic biomarkers, and to aid discovery and generate new hypotheses.
Why this matters
A unified inventory of 413 aging clocks makes it possible to ask which classes of biomarker actually capture distinct biology rather than restating the same age signal. The specific findings — mitotic clocks tracking clonal hematopoiesis subtypes, ‘causal’ clocks flagging cancer risk, and immune-cell clock correlations dissolving once cell-type composition is controlled — sharpen how mechanism pages in this area should cite clock evidence, and expose a gap between how commercial biological-age tests are marketed and what the underlying compendium supports.